Clinical trialPhase 1 / Phase 2Completed
Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 15 June 2017
- Expected end
- 15 June 2019
- Enrollment
- 62 participants
- Sites
- 1
- Primary outcomes
- PFS; OS
- Sponsor
- Other
- Results posted
- No
- Last update
- 2 November 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
In this study, effects of γδT cells on human Pancreatic Cancer in combination with tumor reducing surgery, for example IRE going to be investigated.
Detailed description public domain (ClinicalTrials.gov)
Pancreatic tumor will be removed using tumor reducing surgery such as IRE. PBMC of the healthy donor will be separated from peripheral blood. After making them potential cancer killer γδ T Cell, they will be infused to the patients as an immunotherapy treatment.